269 related articles for article (PubMed ID: 23117580)
41. Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition.
Sharma M; Tollefsbol TO
Exp Cell Res; 2022 Jul; 416(1):113160. PubMed ID: 35447103
[TBL] [Abstract][Full Text] [Related]
42. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL).
Kn H; Bassal S; Tikellis C; El-Osta A
Cancer Biol Ther; 2004 Oct; 3(10):989-94. PubMed ID: 15467427
[TBL] [Abstract][Full Text] [Related]
43. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
[TBL] [Abstract][Full Text] [Related]
44. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.
Yan L; Nass SJ; Smith D; Nelson WG; Herman JG; Davidson NE
Cancer Biol Ther; 2003; 2(5):552-6. PubMed ID: 14614325
[TBL] [Abstract][Full Text] [Related]
45. Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes.
Messier TL; Gordon JA; Boyd JR; Tye CE; Browne G; Stein JL; Lian JB; Stein GS
Oncotarget; 2016 Feb; 7(5):5094-109. PubMed ID: 26783963
[TBL] [Abstract][Full Text] [Related]
46. Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?
Michalak EM; Visvader JE
Mol Oncol; 2016 Dec; 10(10):1497-1515. PubMed ID: 27717710
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of wild yam (Dioscorea villosa) root extract as a potential epigenetic agent in breast cancer cells.
Aumsuwan P; Khan SI; Khan IA; Avula B; Walker LA; Helferich WG; Katzenellenbogen BS; Dasmahapatra AK
In Vitro Cell Dev Biol Anim; 2015 Jan; 51(1):59-71. PubMed ID: 25148825
[TBL] [Abstract][Full Text] [Related]
48. Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.
Arabsolghar R; Azimi T; Rasti M
Mol Biol Rep; 2013 Mar; 40(3):2617-25. PubMed ID: 23242655
[TBL] [Abstract][Full Text] [Related]
49. Fgfr3 is a transcriptional target of Ap2delta and Ash2l-containing histone methyltransferase complexes.
Tan CC; Walsh MJ; Gelb BD
PLoS One; 2009 Dec; 4(12):e8535. PubMed ID: 20046871
[TBL] [Abstract][Full Text] [Related]
50. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
51. Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines.
Vural S; Palmisano A; Reinhold WC; Pommier Y; Teicher BA; Krushkal J
Clin Epigenetics; 2021 Mar; 13(1):49. PubMed ID: 33676569
[TBL] [Abstract][Full Text] [Related]
52. Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Patani N; Jiang WG; Newbold RF; Mokbel K
Anticancer Res; 2011 Dec; 31(12):4115-25. PubMed ID: 22199269
[TBL] [Abstract][Full Text] [Related]
53. The role of histone modifications and variants in regulating gene expression in breast cancer.
Dalvai M; Bystricky K
J Mammary Gland Biol Neoplasia; 2010 Mar; 15(1):19-33. PubMed ID: 20131086
[TBL] [Abstract][Full Text] [Related]
54. Analysis of H3K4me3 and H3K27me3 bivalent promotors in HER2+ breast cancer cell lines reveals variations depending on estrogen receptor status and significantly correlates with gene expression.
Kaukonen D; Kaukonen R; Polit L; Hennessy BT; Lund R; Madden SF
BMC Med Genomics; 2020 Jul; 13(1):92. PubMed ID: 32620123
[TBL] [Abstract][Full Text] [Related]
55. Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications.
Müller I; Wischnewski F; Pantel K; Schwarzenbach H
BMC Cancer; 2010 Jun; 10():297. PubMed ID: 20565761
[TBL] [Abstract][Full Text] [Related]
56. Arsenic alters global histone modifications in lymphocytes in vitro and in vivo.
Pournara A; Kippler M; Holmlund T; Ceder R; Grafström R; Vahter M; Broberg K; Wallberg AE
Cell Biol Toxicol; 2016 Aug; 32(4):275-84. PubMed ID: 27165195
[TBL] [Abstract][Full Text] [Related]
57. Loss of SIRT4 promotes the self-renewal of Breast Cancer Stem Cells.
Du L; Liu X; Ren Y; Li J; Li P; Jiao Q; Meng P; Wang F; Wang Y; Wang YS; Wang C
Theranostics; 2020; 10(21):9458-9476. PubMed ID: 32863939
[No Abstract] [Full Text] [Related]
58. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
[TBL] [Abstract][Full Text] [Related]
59. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells.
Collins HM; Abdelghany MK; Messmer M; Yue B; Deeves SE; Kindle KB; Mantelingu K; Aslam A; Winkler GS; Kundu TK; Heery DM
BMC Cancer; 2013 Jan; 13():37. PubMed ID: 23356739
[TBL] [Abstract][Full Text] [Related]
60. Loss of the Ash2l subunit of histone H3K4 methyltransferase complexes reduces chromatin accessibility at promoters.
Barsoum M; Stenzel AT; Bochyńska A; Kuo CC; Tsompanidis A; Sayadi-Boroujeni R; Bussmann P; Lüscher-Firzlaff J; Costa IG; Lüscher B
Sci Rep; 2022 Dec; 12(1):21506. PubMed ID: 36513698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
